Emerging Therapies in Chronic Lymphocytic Leukemia

Reslan, Lina; Dumontet, Charles

doi:10.5772/29403

Cited by 1 publication

(1 citation statement)

References 86 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GA101 has also showed superior therapeutic efficacy in subcutaneous lymphoma xenograft models of diffuse large B-cell lymphoma and mantle cell lymphoma when used as monotherapy or in combination with cyclophosphamide [ 62 – 65 ]. As compared to rituximab GA101 showed significantly superior B-cell depletion not only in peripheral blood but also in spleen and lymph nodes in non-human primates and hCD20 transgenic mice [ 61 , 63 , 64 , 66 – 68 ]. GA101 demonstrated a favorable safety profile with no dose-limiting toxicities during phase I/II study in patients with relapsed/refractory CD20 positive cells including CLL, DLBCL and other NHLs [ 69 ].…”

Section: Development Of Novel Anti-cd20 Mabsmentioning

confidence: 99%

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response

Singh

Gupta

2015

J Cancer Sci Ther

View full text Add to dashboard Cite

Rituximab has been revolutionized and validated CD20 targeting monoclonal antibody. Although, it is widely used for lymphoma therapy and many patients have been benefited. However significant numbers of patients are refractory or developed resistance to current therapies due to low level of CD20 expression and/or availability on cells surface. Thus development of novel anti-CD20 mAbs with great cell killing ability and enhance CD20 levels on cell surface can potentially exploit lymphoma therapy. In this scenario, we are summarizing the recently developed mAbs against CD20 and compounds that have ability to induce CD20 expression at significant level. We also are providing information regarding combination strategy for use of radiation and anti-CD20 mAbs in vitro. However, it will need to be determined by rigorous at pre-clinical and clinic testing. We hope this review will be beneficial for current research in the area of immunotherapy or radio-immunotherapy.

show abstract